Agents Used in Antiretroviral Therapy
Summary
- The coformulated regimen bictegravir/emtricitabine/tenofovir AF was approved in 2018 as a complete regimen for the treatment of HIV infection in adults
- Who are antiretroviral naive
- As a switch regimen in those who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen for ≥ 3 months with no history of treatment failure and no known substitutions associated with resistance to the individual components[FDA BIC FTC TAF]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content